Search Results 331-340 of 17342 for alopecia

1. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy; with the exception of vitiligo and alopecia. Participating Mayo Clinic ...

2. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma - Mayo Clinic

   ... alopecia or peripheral neuropathy * Received a cumulative dose of corticosteroids equivalent to \>=70 mg of prednisone within the 7 days (Cohort A, B, C, F) ...

3. Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma - Mayo Clinic

   Patients with vitiligo or alopecia; ... Any unresolved toxicity National Cancer Institute (NCI) CTCAE v 5.0 Grade ≥ 2 from previous anticancer therapy, with the ...

4. Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer - Mayo Clinic

   ... alopecia and other non-clinically significant adverse events (AEs); The subject has active brain metastases or epidural disease; subjects with brain ...

5. Febuxostat (oral route) - Mayo Clinic

   Febuxostat is used to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or ...

6. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy. Subjects with treated brain metastases with ...

7. Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement;; Subjects with psoriasis ...

8. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

   4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgment are ...

9. DAREON™-9: A Study To Test How Well Different Doses Of BI 764532 Are Tolerated By People With Small Cell Lung Cancer When Taken Together With A Single Agent Chemotherapy - Mayo Clinic

   Persistent toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia ...

10. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

    Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia. ... alopecia) not requiring systemic treatment, or ...